找到约17条结果 (用时0.1403秒)

  • 深度:T细胞受体疗法治疗实体瘤的机遇和挑战

    T细胞受体(T cell receptor,TCR)疗法和嵌合抗原受体(chimeric antigen receptor,CAR)T细胞疗法是利用患者自身的T淋巴细胞治疗癌症的两类前沿基因疗法。由于CAR-T细胞疗法进来取得的卓越成功,TCR疗法的研究相对不那么引人关注。但是在治疗实体瘤方面,TCR疗法可能比CAR疗法更有优势。“靶向实体瘤来说,T...
    2018/03/20
  • 《Nature》: CAR-T疗法全球市场分析

    本文译自Nature Reviews Drug Discovery,原文标题:The market for chimeric antigen receptor T cell therapies。
    2018/02/12
  • 广州生物院在肺癌CAR-T细胞临床前评估研究中取得进展

    3月16日,中国科学院广州生物医药与健康研究院李鹏研究组在国际学术期刊OncoImmunology上发表题为PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells 的研究成果,在体外肺癌细胞系以及肺癌病人来源的异种移植模型中,验证了CAR-PSCA和CAR-MUC1嵌合抗原受体T细胞的有效性和特异性。
    2017/03/21
  • 【易企说】科济生物董事长:“车”难开?细胞免疫治疗路在脚下

    CAR - T,全称Chimeric Antigen Receptor T-Cell Immunotherapy,即嵌合抗原受体T细胞免疫疗法;原理在于经嵌合抗原受体修饰的T细胞,可以特异性地识别肿瘤相关抗原,使效应T细胞的靶向性、杀伤活性和持久性均较常规应用的免疫细胞高,并可克服肿瘤局部免疫抑制微环境并打破宿主免疫耐受状态
    2016/07/22
  • 癌症免疫细胞治疗知识:CAR-TTCR-T的区别在哪里?

    那么,什么是CAR-TTCR-T呢?CAR-T(Chimeric Antibody Receptor Engineered T Cell)和基因修改的T细胞受体(Gene Modified TCR)。事实上,基因修改的T细胞受体技术的研发也已经有相当长的历史。
    2016/05/25
  • TCR测序服务

    T细胞受体(T cell receptor,TCR)是T细胞表面特异性识别抗原和介导免疫应答的分子,是人类基因组中多态性最高的区域之一,决定着人的免疫系统如何适应环境的变化。
    2015/06/04
  • lncRNA:一个全新的世界

    ...载自生物帮资讯2) 文献出处:Yang L, Lin C,etc. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature. 2013 Aug 29;500(7464):598-602.人类基因组可生成1万多种长链非编码RNA(lncRNA)分子,但人们至今却只知道其中几十种转录物的功能。在2013年《自然》(Nature)杂志上的一篇新研究中,来自加州大学的...
    2014/07/07
  • 【转】Nat Neurosci:神经胶质细胞变化影响小鼠社会性行为

    ...uce some autism-related behavioral and functional connectivity deficits. Mice lacking the chemokine receptor Cx3cr1 exhibit a tra1ient reduction of microglia during the early postnatal period and a co1equent deficit in synaptic pruning. We show that deficient synaptic pruning is associated with weak synaptic tra1mission, decreased functional brain connectivity, deficits in social interaction and i...
    2014/02/27
  • 科学家采用细胞疗法成功治愈急性白血病病人

    ...tic leukemia (B-ALL) that we treated with autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) specific to the CD19 antigen. The overall complete respo1e rate was 88%, which allowed us to tra1ition most of these patients to a standard-of-care allogeneic hematopoietic stem cell tra1plant (allo-SCT). This therapy was as effective in high-risk patients with Philadelphia chromosome...
    2014/02/25
  • 一年4篇Cell一作论文 拉斯克奖得主分享科研经验

    ...ites. Mol. Pharm. 22: 6 19-629.Vale, R.D. and Shooter, E.M. (1983) Conve1ion of nerve growth factor receptor complexes to a slowly dissociating, Triton X-100 i1oluble state by anti-nerve growth factor antibodies. Biochem. 22: 5022-5028.Vale, R.D. and Shooter, E.M. (1983) Epidermal growth factor recepto1 on PC12 cells: alteration of binding properties by lecti1. J. Cell. Biochem. 22: 99-109.Vale, R...
    2013/12/20